Atropine
Atropine is an anticholinergic medication used across multiple injectable and ophthalmic products to treat poisoning by nerve agents or insecticides, slow heart rate emergencies (symptomatic bradycardia and cardiac arrest), and eye conditions including dilated pupils and lazy eye therapy.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 50 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Atropine: Patient Information Guide
A plain-language walkthrough of Atropine — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Atropine is used across several products and routes for a wide range of urgent medical situations and eye conditions.
- Injectable atropine (Atropine Sulfate) treats symptomatic bradycardia (dangerously slow heart rate) and bradyasystolic cardiac arrest
- Injectable atropine acts as an antidote for poisoning by organophosphorus nerve agents, carbamate insecticides, and muscarinic mushrooms
- ATROPEN Auto-Injector is specifically approved for treating organophosphorus nerve agent or carbamate insecticide poisoning in adults and children
- Parenteral Atropine Sulfate is used before and during surgery to reduce saliva and airway secretions and to suppress unwanted nerve reflexes
- Injectable atropine is used to relieve spasms of the gastrointestinal tract, including pylorospasm and hypermotility of the colon
- Injectable atropine is used to relax the GI tract during certain imaging procedures (hypotonic radiography)
- Injectable atropine is used for ureteral and biliary colic (spasm-related pain), bronchial spasm, and urinary tract disorders involving bladder muscle overactivity
- Injectable atropine has been used to help manage parkinsonism-related rigidity and tremor, peptic ulcer, and excess secretions from rhinitis or hay fever
- Atropine sulfate and Isopto Atropine eye drops are used for pupil dilation (mydriasis), cycloplegia, and penalization of the healthy eye in amblyopia (lazy eye) treatment in adults and children aged 3 months and older
- Atropine Sulfate eye ointment is used for mydriasis, cycloplegia, and cycloplegic refraction, and for pupil dilation in inflammatory conditions of the iris and uveal tract
⚙️How it works▾
Atropine blocks a set of receptors in the body called muscarinic receptors — the sites that normally respond to the nerve chemical acetylcholine. By blocking these receptors, atropine prevents acetylcholine from slowing the heart, triggering gland secretions, tightening smooth muscle in the gut and airways, or constricting the pupil. In poisoning by nerve agents or certain insecticides, those chemicals cause an overwhelming flood of acetylcholine activity; atropine counters that flood by blocking the receptors acetylcholine would normally hit.
This blockade is competitive — meaning a high enough concentration of acetylcholine can still partially overcome it. That's why repeated or large doses are sometimes needed in severe poisoning situations.
💊How it's taken▾
Atropine is always given by a healthcare professional — the right route and timing depend entirely on what it's being used for.
- Injectable forms may be given intravenously (IV), intramuscularly (IM), subcutaneously (under the skin), or by other routes depending on the clinical situation; IV is usually preferred when available
- The ATROPEN Auto-Injector is injected into the mid-outer thigh in an emergency and is a single-dose device; three auto-injectors are recommended to be available for each person at risk
- Eye drops and eye ointment are applied directly to the eye; your prescriber will specify how often
- Always follow the prescriber's exact instructions — do not adjust the dose or frequency on your own
🤒Side effects — in detail▾
The most common side effects of atropine are direct results of its action on the body's nervous system.
- Dry mouth
- Blurred vision and light sensitivity (photophobia)
- Fast heart rate (tachycardia) and palpitations
- Flushing, warm or dry skin
- Difficulty urinating or inability to urinate
- Constipation, abdominal bloating, nausea, or vomiting
- Headache and dizziness
- Confusion, especially at higher doses
More serious reactions — including severe heart rhythm problems, hallucinations, seizures, high fever from inability to sweat, acute glaucoma, and severe allergic reactions — require emergency medical attention right away.
⚠️Warnings & precautions▾
- Heart risks: Atropine can cause fast or irregular heart rhythms. In people with coronary artery disease or a recent heart attack, it may trigger or worsen a heart attack. Use only under close monitoring in anyone with heart disease.
- Dangerous overheating: Atropine blocks sweating. In warm environments or during exercise, this can lead to high fever and heat injury — especially in children and after accidental injection.
- Acute glaucoma: Atropine can raise pressure inside the eye and trigger acute glaucoma in susceptible individuals. Tell your doctor if you have narrow-angle glaucoma or are at risk.
- Urinary retention: Atropine can make it difficult or impossible to urinate, especially in people with bladder outflow problems.
- Bowel obstruction: In people with partial pyloric stenosis, atropine may cause complete blockage; watch for GI symptoms.
- Chronic lung disease: Atropine can thicken airway secretions, making breathing harder in people with chronic lung conditions.
- Severe allergic reactions: Anaphylaxis has been reported; seek emergency care for throat swelling, hives, or breathing difficulty.
🔀What it interacts with▾
Atropine has a small number of documented drug interactions to be aware of.
- Pralidoxime: When used together with atropine for nerve agent poisoning, pralidoxime can make atropine's effects appear sooner and more strongly — watch for early signs like rapid heart rate, flushing, and dry mouth
- Barbiturates: Atropine can increase the sedative effect of barbiturates; use together very cautiously, particularly if treating seizures related to atropine toxicity
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Tell your doctor about any heart disease, recent heart attack, or heart rhythm problems — atropine significantly affects heart rate and rhythm
- Tell your doctor if you have narrow-angle glaucoma or are at risk — atropine can trigger an acute attack
- Tell your doctor if you have trouble urinating or a known bladder obstruction
- Tell your doctor if you have chronic lung disease — atropine can thicken secretions in the airways
- Tell your doctor if you have partial pyloric stenosis — atropine may cause complete bowel obstruction
- Pregnant women: atropine crosses the placenta and reaches the fetus; in a life-threatening emergency, treatment should not be withheld, but discuss all risks with your doctor
- Breastfeeding mothers: trace amounts appear in breast milk; consider pumping and discarding milk for 24 hours after a dose before resuming breastfeeding
- Children under 2 and adults over 65 clear atropine more slowly — effects may be more intense and longer-lasting; dosing should be cautious
- Tell your doctor about any prior allergic reaction to atropine
🚑If you take too much▾
Too much atropine causes a recognizable pattern: flushed dry skin, very fast heart rate, widely dilated pupils that don't respond to light, high fever, and blurred vision. At higher levels, a person may become confused, disoriented, or have hallucinations, delirium, or seizures — effects that can last 48 hours or more. In the most severe cases, breathing can fail, coma can develop, and the outcome can be fatal.
Treatment is supportive — maintaining breathing, controlling body temperature (especially in children), managing agitation with a benzodiazepine if needed, and keeping urine output up. Anyone suspected of atropine overdose needs emergency medical care immediately.
📡Pharmacodynamics — effects in the body▾
Atropine's most clinically visible effect is speeding up a slow heart rate by releasing the heart from the braking influence of the vagus nerve. It also dries up secretions from salivary, bronchial, and sweat glands, relaxes smooth muscle in the gut and airways, and widens the pupil. One important caution: at very small doses, atropine can briefly slow the heart before the expected speedup occurs. Large or repeated doses can actually depress breathing rather than stimulate it, and occasionally a large dose causes an abnormal heart rhythm called atrioventricular (A-V) block.
🔬Pharmacokinetics — how your body processes it▾
After an intramuscular injection, atropine is absorbed quickly, with peak blood levels reached around 30 minutes after the shot — and physical activity after the injection can significantly increase how much is absorbed. Atropine is distributed widely throughout the body, crosses the placenta, and appears in breast milk in small amounts. It is mainly broken down in the liver, with 13–50% excreted unchanged by the kidneys, and has a half-life of about 2 to 4 hours in most adults.
Children under 2 and adults over 65 eliminate atropine more than twice as slowly as other age groups, meaning effects last longer in these populations. Notably, organophosphate pesticides can slow the breakdown of atropine in the body.
📦How to store it▾
Store between 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15ºC and 30ºC (between 59ºF and 86ºF) . Protect from light.
📄 Written from Atropine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Atropine — the kind of thing our pharmacy team would talk through with you at the counter.
Why is atropine being given to me — what does it actually do? ▾
What side effects should I expect, and which ones should make me call for help? ▾
I received an ATROPEN injection in an emergency. What should I do next? ▾
Is atropine safe during pregnancy or while breastfeeding? ▾
Are there any medicines I should tell my doctor about before getting atropine? ▾
My child needs atropine — is it safe for kids, and are there any special concerns? ▾
Is Atropine available over the counter? ▾
When was Atropine first available? ▾
Who makes Atropine? ▾
💬 Answers drafted from Atropine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Atropine comes
Atropine is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- ATROPEN Auto-Injector is specifically indicated for treating poisoning by organophosphorus nerve agents or carbamate insecticides in adults and children
- Atropine Sulfate injection is used to temporarily block severe or life-threatening muscarinic effects, including treatment of symptomatic bradycardia (dangerously slow heart rate) and cardiac arrest
- Atropine Sulfate injection is used as an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning
- Parenteral atropine sulfate is used as a pre-surgical medication to reduce saliva and airway secretions, and for gastrointestinal spasms and ureteral or biliary colic
- ATROPEN Auto-Injector is given as a single-dose injection into the mid-outer thigh; it is intended as initial emergency treatment — seek definitive medical care immediately after use
- Atropine Sulfate injection is given by a healthcare professional; intravenous administration is usually preferred, but intramuscular, subcutaneous, endotracheal, and intraosseous routes are possible depending on the clinical situation
- Inspect all injectable atropine solutions for particles or discoloration before use; do not use if the solution is not clear or the seal is not intact
- After first opening, discard any unused portion of Atropine Sulfate injection within 24 hours
Show 2 more strengths Show fewer strengths
Eye drops
How this form is used
- Atropine sulfate ophthalmic solution is used to dilate the pupil (mydriasis) and temporarily paralyze the eye's focusing muscle (cycloplegia) in adults and children 3 months and older
- Isopto Atropine 1% is used for pupil dilation (mydriasis) and cycloplegia
- Both Atropine sulfate and Isopto Atropine 1% are used to penalize the healthy eye in the treatment of lazy eye (amblyopia)
- Apply Atropine sulfate or Isopto Atropine eye drops directly to the eye as directed by your prescriber
- Follow your prescriber's instructions for frequency — do not use more often than directed
- Atropine sulfate ophthalmic solution is indicated for patients aged 3 months and older
Eye ointment
How this form is used
- Atropine Sulfate eye ointment is used for pupil dilation (mydriasis) and cycloplegia
- Atropine Sulfate eye ointment is used for cycloplegic refraction and for pupil dilation in inflammatory conditions of the iris and uveal tract
- Apply Atropine Sulfate eye ointment to the eye as directed by your prescriber
- Follow all instructions on the label regarding frequency and amount
📊 Atropine across the U.S. market
How Atropine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (19) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Atropine is used
A general measure of how commonly Atropine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Atropine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Atropine prescribed? Of the 1,597 medications we measure, Atropine ranks #494 by Medicaid prescriptions — more than 69% of them.
Utilization by Atropine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
atropine sulfate 10 MG/ML Ophthalmic Solution Most dispensed
Summed across the 18 of 41 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1190655
1 ML atropine sulfate 0.4 MG/ML Injection
Summed across the 2 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1666781
10 ML atropine sulfate 0.1 MG/ML Prefilled Syringe
Summed across the 3 of 30 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1190546
atropine sulfate 0.4 MG/ML Injectable Solution
Summed across the 3 of 33 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1190776
1 ML atropine sulfate 1 MG/ML Injection
Summed across the 3 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1190795
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Atropine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 29 of 138 listed Atropine NDCs with Medicaid activity.
🔍 Compare Atropine products
A representative set of FDA-listed product records for Atropine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Eye drops | ||||
| 10 mg/mL | Ophthalmic | A-S Medication Solutions × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | A-S Medication Solutions × 2 listings | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Akorn × 2 listings | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Akorn | NDA AUTHORIZED GENERIC | View NDC → |
| 10 mg/mL | Ophthalmic | Alcon Laboratories, Inc. × 3 listings | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Amneal Pharmaceuticals NY LLC × 9 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Apotex Corp. × 3 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Bausch & Lomb Americas Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 10 mg/mL | Ophthalmic | Bausch & Lomb Americas Inc. | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Bausch & Lomb Incorporated × 2 listings | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Edenbridge Pharmaceuticals LLC. | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Gland Pharma Limited × 3 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Lifestar Pharma LLC × 6 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Mwi | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | NorthStar RxLLC | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Redpharm Drug × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Somerset Therapeutics, LLC × 4 listings | ANDA | View NDC → |
| 💊Eye ointment | ||||
| 10 mg/g | Ophthalmic | AvPAK | UNAPPROVED DRUG OTHER | View NDC → |
| 10 mg/g | Ophthalmic | Bausch & Lomb Incorporated × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 💊Injection | ||||
| 0.1 mg/mL | Intravenous | A-S Medication Solutions × 3 listings | ANDA | View NDC → |
| 0.1 mg/mL | Parenteral | A-S Medication Solutions | UNAPPROVED DRUG OTHER | Find on DailyMed ↗ |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | A-S Medication Solutions | UNAPPROVED DRUG OTHER | Find on DailyMed ↗ |
| 0.05 mg/mL | Intravenous | Accord Healthcare, Inc., × 3 listings | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Accord Healthcare, Inc., × 3 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Accord Healthcare Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Accord Healthcare Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Intravenous | Accord Healthcare Inc. × 2 listings | NDA | View NDC → |
| 1 mg/mL | Intravenous | Accord Healthcare Inc. × 2 listings | NDA | View NDC → |
| 0.4 mg/mL | Intravenous | American Regent, Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | American Regent, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 1 mg/mL | Intravenous | American Regent, Inc. | ANDA | View NDC → |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | American Regent, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Intravenous | Amneal Pharmaceuticals LLC × 5 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Fresenius Kabi USA, LLC | NDA | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Fresenius Kabi USA, LLC | NDA | View NDC → |
| 0.1 mg/mL | Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc | UNAPPROVED DRUG OTHER | View NDC → |
| 0.05 mg/mL | Endotracheal; Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc. | NDA | View NDC → |
| 0.1 mg/mL | Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intravenous | Henry Schein, Inc | ANDA | View NDC → |
| 0.05 mg/mL | Endotracheal, Intramuscular, Intravenous, Subcutaneous | Henry Schein, Inc. | NDA | View NDC → |
| 0.05 mg/mL | Endotracheal; Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | Henry Schein, Inc. × 2 listings | ANDA | View NDC → |
| 0.1 mg/mL | Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. × 4 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Henry Schein, Inc. | NDA | View NDC → |
| 0.4 mg/mL | Intravenous | Henry Schein, Inc. | NDA | View NDC → |
| 1 mg/mL | Intravenous | Henry Schein, Inc. × 2 listings | NDA | View NDC → |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Intravenous | HF Acquisition Co., LLC, DBA Health First × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Intravenous | HF Acquisition Co. LLC, DBA Health First × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 3 listings | ANDA | View NDC → |
| 0.1 mg/mL | Parenteral | HF Acquisition Co LLC, DBA HealthFirst | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Endotracheal, Intramuscular, Intravenous, Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | NDA | View NDC → |
| 0.1 mg/mL | Endotracheal; Intramuscular; Intravenous; Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | NDA | View NDC → |
| 0.4 mg/mL | Intramuscular, Intravenous, Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | ANDA | View NDC → |
| 0.4 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 1 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | ANDA | View NDC → |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intravascular | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | Hikma Pharmaceuticals USA Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 1 mg/mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 0.05 mg/mL | Intravenous | Hospira, Inc. × 2 listings | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | Hospira, Inc. × 4 listings | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | International Medication Systems, Limited × 2 listings | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Medefil, Inc. × 2 listings | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Medical Purchasing Solutions, LLC × 3 listings | ANDA | View NDC → |
| 0.1 mg/mL | Parenteral | Medical Purchasing Solutions, LLC | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Endotracheal, Intramuscular, Intravenous, Subcutaneous | Medical Purchasing Solutions, LLC | NDA | View NDC → |
| 0.4 mg/mL | Intramuscular, Intravenous, Subcutaneous | Medical Purchasing Solutions, LLC | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Medical Purchasing Solutions, LLC × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | Medical Purchasing Solutions, LLC × 3 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intravenous | Medical Purchasing Solutions, LLC × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Intravenous | Medical Purchasing Solutions, LLC × 2 listings | NDA | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Medical Purchasing Solutions, LLC | ANDA | Find on DailyMed ↗ |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | Medical Purchasing Solutions, LLC × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 1 mg/mL | Intravenous | Medical Purchasing Solutions, LLC | NDA | View NDC → |
| 1 mg/mL | Intravenous | Medical Purchasing Solutions, LLC | ANDA | View NDC → |
| 0.25 mg/0.3 mL | Intramuscular | Meridian Medical Technologies LLC | NDA | View NDC → |
| 0.5 mg/0.7 mL | Intramuscular | Meridian Medical Technologies LLC | NDA | View NDC → |
| 1 mg/0.7 mL | Intramuscular | Meridian Medical Technologies LLC | NDA | View NDC → |
| 2 mg/0.7 mL | Intramuscular | Meridian Medical Technologies LLC × 2 listings | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | ProPharma Distribution × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | ProPharma Distribution | NDA | View NDC → |
| 0.4 mg/mL | Intravenous | ProPharma Distribution | ANDA | View NDC → |
| 1 mg/mL | Intravenous | ProPharma Distribution | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Remedyrepack Inc. × 2 listings | NDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Somerset Therapeutics, LLC | ANDA | View NDC → |
| 0.4 mg/mL | Intravenous | Somerset Therapeutics, LLC | ANDA | View NDC → |
| 1 mg/mL | Intravenous | Somerset Therapeutics, LLC | ANDA | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Alchem International Private Ltd | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Amphastar Nanjing Pharmaceuticals, Inc. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Boehringer Ingelheim Pharma GmbH and Co. KG × 2 listings | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | C-squared Pharma Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | C-squared Pharma Sarl | BULK INGREDIENT | View NDC → |
| 1000 g/1000 g | — | Hubei Biocause Heilen Pharmaceutical Co., Ltd | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Kalchem International inc | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Laurus Labs Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Letco Medical, Llc | BULK INGREDIENT | View NDC → |
| 1 g/g | — | MEDISCA Inc.. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Minsheng Group Shaoxing Pharmaceutical Co,. Ltd. × 2 listings | BULK INGREDIENT | View NDC → |
| 35 kg/35 kg | — | Nuray Chemicals Private Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Professional Compounding Centers of America dba PCCA | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Rolabo Outsourcing, S.L. × 2 listings | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | SCL Lifesciences Limited | BULK INGREDIENT | View NDC → |
| 4 kg/4 kg | — | Siegfried Grafton, Inc. | BULK INGREDIENT | View NDC → |
Showing 192 of 192 products — FDA National Drug Code Directory. See every product, package size and price: browse all 192 Atropine NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Atropine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Atropine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Atropine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1223 7 dose forms · 28 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 1668013In current FDA listingsClinical drug / strength (SCD) 0.3 ML atropine sulfate 0.833 MG/MLRxCUI 11905360.7 ML atropine sulfate 0.714 MG/MLRxCUI 11905380.7 ML atropine sulfate 1.43 MG/MLRxCUI 11905400.7 ML atropine sulfate 2.86 MG/MLRxCUI 1190542 -
Dose form (SCDF) Injectable Solution RxCUI 370624In current FDA listingsClinical drug / strength (SCD) sulfate 0.3 MG/MLRxCUI 1190764sulfate 0.4 MG/MLRxCUI 1190776sulfate 0.54 MG/MLRxCUI 1145629sulfate 0.6 MG/MLRxCUI 1190787sulfate 1.25 MG/MLRxCUI 1190800 -
Dose form (SCDF) Injection RxCUI 1666780In current FDA listingsClinical drug / strength (SCD) 1 ML atropine sulfate 0.4 MG/MLRxCUI 16667811 ML atropine sulfate 1 MG/MLRxCUI 1190795 -
Dose form (SCDF) Ophthalmic Ointment RxCUI 374552In current FDA listings -
Dose form (SCDF) Ophthalmic Solution RxCUI 370964In current FDA listingsClinical drug / strength (SCD) sulfate 0.31 MG/MLRxCUI 1190766sulfate 0.62 MG/MLRxCUI 1190790sulfate 1 MG/MLRxCUI 1190796sulfate 1.25 MG/MLRxCUI 1190801sulfate 10 MG/MLRxCUI 1190655sulfate 2.5 MG/MLRxCUI 1190806sulfate 20 MG/MLRxCUI 1190817sulfate 5 MG/MLRxCUI 1190668 -
Dose form (SCDF) Oral Tablet RxCUI 370625No current FDA listingClinical drug / strength (SCD) sulfate 0.4 MGRxCUI 1190692sulfate 0.6 MGRxCUI 1190783 -
Dose form (SCDF) Prefilled Syringe RxCUI 727389No current FDA listingClinical drug / strength (SCD) 1 ML atropine sulfate 0.4 MG/MLRxCUI 12933115 ML atropine sulfate 0.05 MG/MLRxCUI 11905515 ML atropine sulfate 0.1 MG/MLRxCUI 11905525 ML atropine sulfate 0.4 MG/MLRxCUI 119055610 ML atropine sulfate 0.1 MG/MLRxCUI 1190546
Look up RxCUI 1223 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Atropine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
…and 16 more on the FDA NDC directory.
RxNorm drug class
Atropine belongs to the Anticholinergic class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 50 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Meridian Medical Technologies LLC is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.